Ipamorelin — Dosing & Research | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

Ipamorelin

Also known as: NNC 26-0161, IPA, Ipamorelin acetate, Aib-His-D-2-Nal-D-Phe-Lys-NH2

Growth Hormone Secretagogue (GHS); Ghrelin Receptor Agonist; Synthetic Pentapeptide

Not FDA-approvedLast updated: October 29, 2026Based on 26 peer-reviewed studies

What it is

Ipamorelin is a peptide people use to boost their body's own growth hormone output. It's taken for muscle recovery, body composition, better sleep, and recovery after illness or surgery. Not FDA-approved; classified as investigational.

The scientific side

Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) and selective growth hormone secretagogue (GHS) that acts as an agonist at the ghrelin receptor (GHS-R1a), stimulating growth hormone (GH) release from the anterior pituitary. Its GH-releasing potency and efficacy in vitro are similar to GHRP-6 (EC50 = 1.3 nmol/L), and it stimulates GH release via a GHRP-like receptor mechanism. Unlike GHRP-2 and GHRP-6, ipamorelin does not significantly elevate ACTH or cortisol at doses more than 200-fold above its GH-releasing ED50 in swine, making it the first described GHS with selectivity for GH release analogous to GHRH. Pharmacokinetic-pharmacodynamic modeling in healthy male volunteers demonstrated dose-proportional kinetics with a short terminal half-life of approximately 2 hours, clearance of 0.078 L/h/kg, and volume of distribution at steady state of 0.22 L/kg; it induces a single episode of GH release peaking at ~0.67 hours. Ipamorelin is described as a growth hormone secretagogue that activates IGF-1 signaling and satellite cell repair pathways. It also exerts GI promotility effects via ghrelin receptor-mediated cholinergic mechanisms, stimulates insulin secretion via calcium channel and adrenergic receptor pathways, and may act peripherally to attenuate visceral and somatic nociception.

Class: Growth Hormone Secretagogue (GHS); Ghrelin Receptor Agonist; Synthetic Pentapeptide

Not FDA-approvedLow researchHormonesGrowth hormone-releasing peptide (GHRP)

At a glance

What it isA synthetic 5-amino-acid peptide that triggers growth hormone release through the ghrelin receptor.
FDA statusNot approved for any use. On FDA's list of compounding substances with significant safety risks (503B, since 2023).
Used forRaising growth hormone and IGF-1 for recovery, body composition and sleep, without direct human evidence for those uses.
Human evidenceOne PK study in 40 healthy men and two IV trials for post-surgical bowel recovery; the published one missed its main goal.
Half-lifeAbout 2 hours (IV, healthy men).
Banned in sportYes. WADA names it under S2.2.4 (growth hormone releasing factors), prohibited at all times.

What is Ipamorelin?

Ipamorelin is a synthetic pentapeptide (5 amino acids) developed by Novo Nordisk in the 1990s under the code NNC 26-0161. It belongs to the growth hormone-releasing peptides (GHRPs), alongside GHRP-6 and GHRP-2.

It is often paired with a GHRH analog such as CJC-1295, which acts on a different pituitary receptor.

Sources: [1]

How does it work?

Ipamorelin activates the ghrelin receptor (GHS-R1a) on the pituitary, which releases a pulse of growth hormone. Growth hormone then raises IGF-1.

What made it stand out was selectivity. In pigs, older GHRPs raised ACTH and cortisol, but "ipamorelin did not release ACTH or cortisol in levels significantly different from those observed following GHRH stimulation", even at doses over 200 times the effective dose. None of the peptides tested changed FSH, LH, prolactin or TSH. These are animal results; they have not been confirmed in human trials.

Pharmacokinetics

Half-lifeAbout 2 hours (terminal; IV in 40 healthy men)
MetabolismModerately resistant to breakdown: 60-80% of the dose recovered from bile and urine as intact peptide in rats
Clearance0.078 L/h/kg in healthy men (IV); excreted mainly in urine in rats
RouteStudied IV in humans; sold for injection under the skin

Sources: [1] [2] [3]

Is it FDA-approved?

No. Ipamorelin has never been approved for any use.

FDA added ipamorelin acetate to its list of compounding substances with significant safety risks (503B Category 2) in September 2023. FDA cited immunogenicity and its unnatural amino acids, and noted that "a study published in literature identified serious adverse events including death when ipamorelin was administered intravenously for improving gastric motility". That refers to IV use in hospitalized surgical patients, not to the injections people take at home, for which FDA says it has no safety information.

In October 2024, FDA's Pharmacy Compounding Advisory Committee voted 0-12, with 1 abstention, against adding ipamorelin to the 503A bulks list.

  • WADA: S2.2.4 Growth hormone releasing factors (named among growth hormone secretagogues; prohibited at all times)

Sources: [4] [5]

History

Novo Nordisk published ipamorelin in 1998 as "the first selective growth hormone secretagogue", and a 1999 study in 40 healthy men described its pharmacokinetics.

Development then moved to Helsinn, which tested IV ipamorelin to speed bowel recovery after surgery (postoperative ileus). The phase 2 trial, run from 2008 to 2009 and published in 2014, did not meet its main goal, and no company has pursued approval since. Ipamorelin now circulates mainly as an unregulated research peptide.

Sources: [1] [2] [6] [7]

Regulatory timeline

  1. September 29, 2023FDA places ipamorelin acetate in Category 2 for 503B outsourcing facilities, citing immunogenicity, unnatural amino acids and serious adverse events with IV use for gastric motility. Source
  2. October 29, 2024FDA's Pharmacy Compounding Advisory Committee votes 0-12, with 1 abstention, against adding ipamorelin (free base and acetate) to the 503A bulks list. Source
  3. As of October 2026Still in 503B Category 2 and not FDA-approved. It was not on the July 2026 advisory committee agenda. Source

Side effects

In the published ileus trial (114 surgical patients, IV 0.03 mg/kg twice daily for up to 7 days), adverse events were common in both groups (87.5% on ipamorelin versus 94.8% on placebo), and the authors judged it well tolerated. FDA's note about serious adverse events including death comes from this IV, post-surgical setting.

There are no published trials of the under-the-skin injections people use, so their side effects are not known from controlled data. Because it raises growth hormone and IGF-1, effects seen with other growth hormone secretagogues, such as water retention and higher blood sugar, are plausible but unstudied.

Who should not use it

  • No established contraindications: ipamorelin has never been through approval trials.
  • Competitive athletes: prohibited at all times under WADA S2.2.4.
  • Active cancer: it raises growth hormone and IGF-1, growth factors that approved GH-releasing drugs list as a contraindication.
  • Pregnancy and breastfeeding: not studied.

Only one published efficacy trial: 114 surgical patients given IV ipamorelin or placebo; treatment-emergent adverse events 87.5% vs 94.8%.

Sources: [6] [4]

What does the research show?

In rats and pigs, ipamorelin released growth hormone about as strongly as GHRP-6 but more selectively. In 40 healthy men given IV doses, it had a terminal half-life of about 2 hours and raised growth hormone in proportion to the dose.

The only published efficacy trial tested it after bowel surgery: median time to tolerate a solid meal was 25.3 hours on ipamorelin versus 32.6 hours on placebo, not a significant difference (p = 0.15). No published human trial has measured muscle, fat loss, sleep or anti-aging outcomes.

Studied for

  • Postoperative ileus after bowel surgery (phase 2, IV; missed its main goal)
  • Growth hormone release and selectivity (rats and pigs)
  • Pharmacokinetics in healthy men (IV)

Sources: [1] [2] [6]

FAQ

Is Ipamorelin FDA-approved?

No. It has never been approved for any use, and its one published efficacy trial missed its main goal.

Sources: [6]

Did people die from Ipamorelin?

FDA notes serious adverse events including death in a study where ipamorelin was given IV to improve gut motility, in hospitalized surgical patients. That is a different setting from home injections, and the published trial reported similar adverse-event rates on ipamorelin and placebo.

Sources: [4] [6]

Does Ipamorelin raise cortisol or prolactin?

Not in the animal studies that defined it: in pigs it did not raise ACTH or cortisol beyond GHRH levels, and it did not change prolactin, FSH, LH or TSH. This has not been tested in human trials.

Sources: [1]

Can a compounding pharmacy make Ipamorelin?

FDA lists ipamorelin acetate as a significant safety risk for 503B outsourcing facilities, and its advisory committee voted 0-12 against adding it to the 503A bulks list in 2024.

Sources: [4] [5]

What is Ipamorelin's half-life?

About 2 hours after IV dosing in healthy men. There is no published human data for under-the-skin injection.

Sources: [2]

Is Ipamorelin banned in sport?

Yes. The 2026 WADA Prohibited List names ipamorelin under S2.2.4, prohibited at all times.

Sources: [8]

Does Ipamorelin build muscle or burn fat?

There is no human trial evidence. No published human study has measured body composition with ipamorelin.

Sources: [6]

Citations

  1. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol 1998. PMID 9849822
  2. Gobburu JV, et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res 1999. PMID 10496658
  3. Johansen PB, et al. Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption. Xenobiotica 1998. PMID 9879640
  4. FDA: Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of April 22, 2026). fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
  5. FDA: final summary minutes of the Pharmacy Compounding Advisory Committee meeting, October 29, 2024. fda.gov/media/185412/download
  6. Beck DE, et al. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis 2014. PMID 25331030
  7. NCT00672074: Safety and efficacy of ipamorelin for management of post-operative ileus (Helsinn). clinicaltrials.gov/study/NCT00672074
  8. World Anti-Doping Agency: Prohibited List 2026 (copy hosted by SEGAS). segas.gr/wp-content/uploads/2025/11/2026list_en_final_clean_september_2025.pdf

Sources

Administration & storage

Administration
Intravenous infusion (PMID: 2533103010496658192895671062916527186127)Subcutaneous injection (PMID: 10373343117352441082884011162489)Subcutaneous via osmotic minipump (PMID: 10828840)Intraperitoneal injection (PMID: 39043357)Intranasal (pharmacokinetic study in rats~20% bioavailability) (PMID: 9879640)Nasal administration in humans (excretion/metabolite study) (PMID: 25869809)
Storage
One abstract notes that -20°C is the appropriate storage temperature for small peptides including ipamorelin in urine samples for sports drug testing purposes. No abstract specifies storage conditions for pharmaceutical preparations of ipamorelin intended for clinical or research use.
Cautions
Ipamorelin is not approved by the FDA or other major regulatory agencies for performance or musculoskeletal indications; use outside of approved/investigational protocols carries unknown safety risks.,Long-term safety data in humans are absent; reviewed literature notes a 'current lack of clinical trials' and that 'rigorous human safety data are scarce'.,Gray-market peptide products may be mislabeled, contaminated, or contain analogs (e.g., Gly-Ipamorelin) with unknown pharmacological and safety profiles.,Ipamorelin is listed on the WADA Prohibited List; athletes should be aware of antidoping implications and detection in urine.,Reported adverse effects class-wide for GHS include endocrine/metabolic disturbances (prolactin and cortisol elevations, appetite changes, dysglycaemia), fluid retention, musculoskeletal symptoms, and injection-site reactions.,Sterile technique for any injection is essential; use of unregulated supply chain products introduces additional contamination risks.

Legal & regulatory status

US FDA

Not stated in reviewed literature as FDA-approved for any indication. Reviewed literature describes ipamorelin as an unapproved/investigational compound for performance and musculoskeletal indications. A Phase II RCT…

WADA

Listed on the WADA Prohibited List as a prohibited substance (PMID: 13578461 [not in corpus]; per PMID: 26578461, ipamorelin is listed among prohibited substances <2 kDa on the WADA Prohibited List; PMID: 41880199 notes…

Health Canada

Not stated in reviewed literature — requires manual verification.